Allurion Technologies Holdings Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allurion Technologies reports Q3 revenue decline, eyes FDA approval

Allurion Technologies Holdings Inc faced challenges in Q3 due to the suspension of the Allurion Balloon in France and macro headwinds, leading to a decrease in revenue. However, the company highlighted strengths in the Middle East and Latin America, with plans to double revenues by year-end and pursue FDA approval for the Allurion Balloon.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working.

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for its Virtual Care Suite (VCS) in the United States. With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1.

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

NATICK, Mass.--(BUSINESS WIRE)--Allurion to Participate in Two Upcoming Investor Conferences in June 2024.

Allurion to Participate in Two Upcoming Investor Conferences in June 2024

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion's proprietary behavior change program. This study was cond.

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

Allurion Technologies Inc. (NYSE:ALUR ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations, ICR Westwicke Shantanu Gaur - Chief Executive Officer Chris Geberth - Chief Financial Officer Conference Call Participants Matthew Taylor - Jefferies Keay Nakae - Chardan Operator Thank you for standing by and welcome to the Allurion First Quarter Earnings Call. All lines have been placed on mute to prevent any background noise.

Allurion Technologies Inc. (ALUR) Q1 2024 Earnings Call Transcript

NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports First Quarter 2024 Financial Results and Provides Business Update.

Allurion Reports First Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three oral scientific presentations at the 12th Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders – European Chapter (IFSO-EC) held in Vienna, Austria on 2-4 May 2024. Presentations include data from a survey of 133 patients across seven international obesity centers that shows patients on the Allurion Program lost just over 1.

Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024. Management expects preliminary unaudited results for the period as follows: Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023 Procedural volume growth, as estimated by new app users, reflecting 22% growth ove.

Allurion Announces Preliminary First Quarter 2024 Results

NATICK, Mass.--(BUSINESS WIRE)--Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments.

Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Little-known medical device firm Allurion (NYSE: ALUR ) — which is focused on ending obesity via its swallowable and “procedure-less” intragastric balloon — saw its shares skyrocket on Thursday. Earlier this morning, management announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the U.S. ALUR stock likely benefited from rising interest in anti-obesity treatments.

Why Is Allurion (ALUR) Stock Up 65% Today?

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States. Already in use by thousands of providers in over 50 countries, the VCS is a dynamic weight-loss management suite powered by artificial intelligence (AI) featuring remote patient monitoring, telehealth and care team collaboration all under the one digital umbrella, designed.

Allurion Expands Virtual Care Suite to the United States

Allurion Technologies Inc. (ALUR) Q4 2023 Earnings Call Transcript

NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance.

Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in the company's history and is a proven and dynamic leader, with deep experience as an operator and board member," said Dr. Shantanu Gaur, Allurion Founder and CEO. "Her perspective and gu.

Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair

NATICK, Mass.--(BUSINESS WIRE)--Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024.

Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins Allurion with nearly 20 years' experience as a chief legal and compliance officer at three separate public companies. Most recently, Brendan served as Executive Vice President and Chief Legal Officer at Acushnet Company, the parent company of Titleist and other golf.

Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for ap.

Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's largest aesthetic and weight loss clinic chain. After recently expanding its commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for.

Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide. In the study, 115 patients were randomized to either the Allurion Program with.

Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities

NATICK, Mass.--(BUSINESS WIRE)--Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook.

Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake. The global market for anti-obesity medications – specifically of GLP-1s (glucagon-like peptide-1 receptor agonists) – is expected to reach $100 billion by 2030.1 Research has shown these products have significantly alte.

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for weight loss—and the hiring of Brian Conyer to lead commercialization of Allurion's rapidly growing digital assets. After a successful 2023 in which it managed over 2,000 patients on Allurion's Virtual Care Suite (VCS) digital platform, Weight Doctors has sig.

Allurion's Digital Platform Gains Traction with Expanded Strategic Partnership

Allurion Technologies Inc. (NYSE:ALUR ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Mike Cavanaugh - ICR of Westwicke Shantanu Gaur - Founder and Chief Executive Officer Chris Geberth - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Ross Osborn - Cantor Fitzgerald Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Operator Hello, and welcome to the Allurion Third Quarter Earnings Call. All lines have been placed on mute to prevent any background noise.

Allurion Technologies Inc. (ALUR) Q3 2023 Earnings Call Transcript

NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update.

News for Allurion Technologies Holdings Inc Stock (ALUR)